People
Back by popular demand, AmorChem, the innovative Quebec-based seed venture capital fund, is hosting the 5thedition of its KNOCK OUTTM Event, a challenge where the Contenders, academic researchers selected by AmorChem, duke it out in the ring against a panel of Heavyweight champions in order to qualify for a $500,000 financing from AmorChem.
On Friday, March 8, Bristol-Myers Squibb executives met with sell-side analysts to sell its $74 billion Celgene buyout.
The Federal Bureau of Prisons is investigating reports that Pharma Bro Martin Shkreli is using a contraband cellular telephone to continue to call the shots at his former company from prison.
As drugmakers continue to develop an understanding of what pain is to the human body, it helps drive the development of innovative manners to treat it that transcend addictive options such as opioids.
After Allergan reported that its late-stage adjunctive treatment for major depressive disorder failed to distinguish itself against placebo, hedge fund investor Appaloosa LP is again calling on the Ireland-based company to make some changes to its board of directors, including tapping a new chairman.
Martin Shkreli may be behind bars, but that doesn’t mean he does not take a direct hand in running Turing Pharmaceuticals, the company that has been redubbed Phoenixus AG. The WSJ reports that Shkreli is still very much involved in the leadership of the company he founded.
Strategic Senior Appointment Spearheads Compelling Work Culture for Continued Success
Aphria Inc. President, Jakob Ripshtein, is proposed to replace Mr Battersby as Non-Executive Director (pending ODC approval)
Dirk de Naeyer appointed Chief Operations Officer and Martine Nolan as Head of Quality Assurance, effective March 1, 2019
Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
PRESS RELEASES